prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |review
In this study patients with diabetes (3570 subjects) which were at high cardiovascular risks, with hypertension or already on antihypertensive therapy, initially were randomized either to ramipril ( increasing to 10 mg daily) or to placebo.

In those randomized to ramipril there was 25% lower risk of macrovascular disease and 37% lower risk of cardiovascular death.